摘要
目的:探讨我国《药品差比价规则》(以下简称《规则》)存在的局限性。方法:以硝苯地平为例,通过比较硝苯地平片剂与硝苯地平控/缓释制剂疗效、不良反应、日治疗费用、生产工艺,粗略核算硝苯地平控释片生产成本,分析硝苯地平控释片未列入2012年版《国家基本药物目录》的可能原因,进而分析我国《规则》的局限性。结果与结论:改剂型药品虽然在某种程度上提高了治疗效果,减少了不良反应,让患者使用更方便,但价格成本核算不到位,药品差价过高,导致部分药品部分剂型价格"虚高"现象存在,限制和削弱了《规则》的积极作用。建议尽快将未作差比价系数规定的剂型、规格逐步进行补充和完善,尤其是控释制剂、靶向制剂等。
OBJECTIVE：To explore the limitations of Regulation of Drug Price Difference（called Regulation for short） in China.METHODS：Taking nifedipine as an example,the cost of Nifedipine controlled release tablet was calculated roughly by comparing therapeutic efficacy,ADR,DDC and preparation technology between Nifedipine tablet and Nifedipine controlled-release tablets.The reasons that Nifedipine controlled-release tablets had not been included in National Essential Medicine List（2012 edition） were analyzed,and the limitation of regulation were also analyzed.RESULTS CONCLUSIONS：The change of dosage form improve therapeutic efficacy to some extent,reduce adverse reactions and drugs are more convenient to patient;but the cost accounting is not in place and medicine difference is too high,which lead to false high prices of part of dosage form,inhibit and weaken the active effect of regulation.The dosage form and specification without price difference coefficient should be supplemented and improved regularly as soon as possible,especially controlled release preparation and targeting preparation.
出处
《中国药房》
CAS
CSCD
2013年第20期1850-1852,共3页
China Pharmacy
关键词
硝苯地平
硝苯地平片
缓释片
控释片
药品差比价规则
局限性
Nifedipine
Nifedipine tablets
Sustained release tablets
Controlled release tablets
Regulation of drug price difference
Limitation
